

Mr. Bornstein was the General Manager of Bristol-Myers Squibb (Israel), until 1992. He subsequently founded Pharmateam Ltd., an Israeli company that successfully specialized in representing International pharmaceutical companies such as 3M Health Care, G.D. Searle, Shire, Medimmune, United Therapeutics, Forest Laboratories, Goldshield and others. In a relatively short period Pharmateam reached multi-million dollar turnover and profitability. Pharmateam was sold in 2000, when Mr. Bornstein founded Shizim Ltd and through it all its subsidiaries.

Mr. Bornstein's activity is not only recognized and appreciated in the business world, but also on a national level. He served as the Biotechnology Committee Chairman of USISTC (United States-Israel Science & Technology Commission), and also as a consultant for USISTF (United States-Israel Science & Technology Foundation). Through these organizations Mr. Bornstein has initiated, founded and led a number of major national level projects for the Israeli life-science industry and for the State of Israel. Amongst these: ILSI (Israel Life Science Industry Organization) – the biggest organization in Israel for representing the mutual goals of the Israeli life science community [recently merged into IATI], and ITTN (Israel Technology Transfer Organization), which serves as the umbrella organization for Israel's academic Technology Transfer Offices (the Israeli equivalent of AUTM in the US), holding all innovative technologies from the entire Israeli academia.

Mr. Bornstein is a Committee Member at The Life Science Forum of IPCC– the Israeli-Palestinian Chamber of Commerce, and has also served as a member of the Advisory Board – Life Science Industry, The Israel Export & International Cooperation Institute.